Literature DB >> 12390970

Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease.

Antony J Harding1, Emily Stimson, Jasmine M Henderson, Glenda M Halliday.   

Abstract

The amygdala exhibits significant pathological changes in Parkinson's disease, including atrophy and Lewy body (LB) formation. Amygdala pathology has been suggested to contribute to some clinical features of Parkinson's disease, including deficits of olfaction and facial expression. The degree of neuronal loss in amygdala subnuclei and the relationship with LB formation in non-demented Parkinson's disease cases have not been examined previously. Using stereological methods, the volume of neurones and the number of neurones in amygdala subdivisions were estimated in 18 prospectively studied, non-demented patients with Parkinson's disease and 16 age- and sex-matched controls. Careful exclusion (all cortical disease) and inclusion (non-demented, levodopa-responsive, idiopathic Parkinson's disease or controls) criteria were applied. Seven Parkinson's disease cases experienced well-formed visual hallucinations many years after disease onset, while nine Parkinson's disease cases and three controls were treated for depression. Anatomically, the amygdala was subdivided into the lateral nucleus, the basal (basolateral and basomedial) nuclei and the corticomedial (central, medial and cortical nuclei) complex. LB and Lewy neurites were identified by immunohistochemistry for alpha-synuclein and ubiquitin and were assessed semiquantitatively. LB were found throughout the amygdala in Parkinson's disease, being present in approximately 4% of neurones. Total amygdala volume was reduced by 20% in Parkinson's disease (P = 0.02) and LB concentrated in the cortical and basolateral nuclei. Lewy neurites were present in most cases but did not correlate with any structural or functional variable. Amygdala volume loss was largely due to a 30% reduction in volume (P = 0.01) and the total estimated number of neurones (P = 0.007) in the corticomedial complex. The degree of neurone loss and the proportion of LB-containing neurones in the cortical nucleus within this complex were constant across Parkinson's disease cases and neither variable was related to disease duration (R(2 )< 0.03; P > 0.5). The cortical nucleus has major olfactory connections and its degeneration is likely to contribute to the early selective anosmia common in Parkinson's disease. There was a small reduction in neuronal density in the basolateral nucleus in all Parkinson's disease cases, but no consistent volume or cell loss within this region. However, the proportion of LB-containing neurones in the basolateral nucleus was nearly doubled in cases that exhibited visual hallucinations, suggesting that neuronal dysfunction in this nucleus contributes to this late clinical feature. Detailed quantitation of the other amygdala subdivisions failed to reveal any other substantial anomalies or any associations with depression. Thus, the impact of Parkinson's disease on the amygdala is highly selective and correlates with both early and late clinical features.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390970     DOI: 10.1093/brain/awf251

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  85 in total

Review 1.  Premotor Diagnosis of Parkinson's Disease.

Authors:  Heinz Reichmann
Journal:  Neurosci Bull       Date:  2017-08-03       Impact factor: 5.203

Review 2.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Emotion and ocular responses in Parkinson's disease.

Authors:  J Dietz; M M Bradley; M S Okun; D Bowers
Journal:  Neuropsychologia       Date:  2011-08-04       Impact factor: 3.139

4.  Startle reflex hyporeactivity in Parkinson's disease: an emotion-specific or arousal-modulated deficit?

Authors:  K M Miller; M S Okun; M Marsiske; E B Fennell; D Bowers
Journal:  Neuropsychologia       Date:  2009-03-13       Impact factor: 3.139

5.  The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease.

Authors:  James M Shine; Glenda M Halliday; Moran Gilat; Elie Matar; Samuel J Bolitho; Maria Carlos; Sharon L Naismith; Simon J G Lewis
Journal:  Hum Brain Mapp       Date:  2013-06-13       Impact factor: 5.038

6.  Advances in the treatment of visual hallucinations in neurodegenerative diseases.

Authors:  Daniel Collerton; John-Paul Taylor
Journal:  Future Neurol       Date:  2013-07

Review 7.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

Review 8.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

Review 9.  The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.

Authors:  Walter J Schulz-Schaeffer
Journal:  Acta Neuropathol       Date:  2010-06-20       Impact factor: 17.088

10.  Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.

Authors:  Ming Tong; Matthew Dong; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.